Skip to content

Drug interactions

Ixazomib + Lenacapavir

Severity: Minor

Ixazomib and Lenacapavir: minor interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Lenacapavir is a moderate CYP3A inhibitor with a very long half-life after subcutaneous dosing. Ixazomib exposure may rise modestly, but it is not heavily dependent on CYP3A.

What this interaction means in plain words

Ixazomib and Lenacapavir have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.

Ixazomib belongs to Oncology; Lenacapavir belongs to Anti Virals.

Evidence level: Low

Why it happens

Lenacapavir inhibits CYP3A4, which may modestly reduce ixazomib metabolism.

What to do

No empirical dose change is needed; monitor for ixazomib adverse effects, including after lenacapavir has been stopped given its prolonged exposure.

What to ask your pharmacist

  • Is there anything I should notice while taking both?
  • Do I need to tell my doctor at the next visit?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Ixazomib and Lenacapavir, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Ixazomib with Lenacapavir?

MediHelp rates the interaction as minor. Ixazomib and Lenacapavir have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Lenacapavir is a moderate CYP3A inhibitor with a very long half-life after subcutaneous dosing. Ixazomib exposure may rise modestly, but it is not heavily dependent on CYP3A.

How serious is the interaction between Ixazomib and Lenacapavir?

MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No empirical dose change is needed; monitor for ixazomib adverse effects, including after lenacapavir has been stopped given its prolonged exposure.

What other medicines interact with Ixazomib?

MediHelp also lists interactions of Ixazomib with, for example, Apalutamide, Carbamazepine, Dabrafenib. The full list is on the Ixazomib page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in